GlassScriptPhysician profile
William W Henderson
NPI 1497755680
$4,949.28
in general payments reported to CMS, 2019-2025
31 companies · $13.94 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,662 · 2020: $927 · 2021: $1,345 · 2022: $970 · 2023: $14.43 · 2024: $16.48 · 2025: $13.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $44.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $44.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,154.55 | 2019-2022 | |
| Glaxosmithkline, LLC. | $1,083.88 | 2019-2022 | |
| Genzyme Corporation | $300.72 | 2019-2022 | |
| Genentech USA, INC. | $298.08 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $264.91 | 2019-2022 | |
| Philips North America LLC | $232.01 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $213.14 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.77 | 2019-2022 | |
| Mylan Specialty L.P. | $189.70 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $131.70 | 2019 | |
| Mallinckrodt Hospital Products INC. | $127.68 | 2020-2021 | |
| Amgen INC. | $118.38 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $80.68 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $52.35 | 2020-2022 | |
| Electromed, INC. | $51.25 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $44.85 | 2023-2025 | Atellica Ch 930 Analyzer, Atellica Im 1300 Analyzer |
| Merck Sharp & Dohme LLC | $44.80 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.67 | 2021-2022 | |
| Pfizer INC. | $37.34 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $36.05 | 2022 | |
| Circassia INC. | $31.88 | 2019-2020 | |
| Gilead Sciences, INC. | $26.67 | 2021 | |
| Vifor Pharma, INC. | $25.72 | 2021 | |
| Sanofi-Aventis U.S. LLC | $25.28 | 2021 | |
| Allergan, INC. | $21.08 | 2019 | |
| Tactile Systems Technology INC | $20.48 | 2021 | |
| Csl Behring | $18.31 | 2021 | |
| Ani Pharmaceuticals, INC. | $16.90 | 2022 | |
| Uswm, LLC | $16.15 | 2021 | |
| La Jolla Pharmaceutical Company | $15.54 | 2021 | |
| Advanced Respiratory, INC | $13.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.